Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population
Study Details
Study Description
Brief Summary
This is a 2 parallel-arm randomized controlled study with free-living subjects on self-selected diets. The objective of this study is to compare the effects of two servings of peanuts with an isocaloric matched refined carbohydrate snack food on glucose, lipids and lipoproteins and cardiovascular health risk factors, satiety and gut microbiota in 250 Chinese participants at risk for metabolic syndrome (overweight/obese, enlarged waist circumference, elevated LDL-cholesterol, prehypertension, and/or prediabetes).
The investigators hypothesize that the inclusion of 2 serving of peanuts in the diet will decrease blood glucose, LDL-cholesterol, and improve satiety sanctification between meals and gut microbiota compared to the control group and baseline.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Emerging evidence has shown that peanut consumption has beneficial effects in modifying lipid profiles, glucose, and other cardiometabolic risk factors. During the last two decades, China has experienced a dramatic increase in T2D prevalence largely due to rapid social and economic growth. Peanuts are commonly consumed as snacks in China. However, there is limited evidence on the specific health benefits of peanuts as part of the Chinese habitual diet.
Clinical Study Protocol
Study diet Subjects will consume their habitual diet with the test snacks provided as roasted peanuts and rice flour snack bars twice a day during a mid- morning snack and mid -afternoon snack. Subjects in the peanut group will consume two serving of peanuts and subjects in the control group will consume isocaloric rice bars on a daily basis under on site supervision. Subjects will be instructed to maintain their habitual diet and physical activity. During the study period, body weight will be monitored routinely to ensure that baseline weight does not fluctuate by more than 1kg. Prior to day 1, day 42 and day 84, a three-day diet record will be administered to subjects to calculate basal energy intake.
Study design The study is a randomized, controlled, parallel-arm trial precedes by a 1-week run-in period with control treatment to assess compliance, acceptability and to determine baseline values.After the run-in period, participants will be randomized to either the control group or treatment group for three months. Each treatment phase will be 3 months in duration. At baseline, day 42 and day 84, clinical assessment (body weight, waist/hip circumference, blood pressure, pulse) will be preformed and blood samples will be collected. Urinary will be collected on baseline, day 42 and day 84. Fecal samples will be collected on baseline and day 84. Three days dietary records and appetite sensation ratings will be collected three times during the study (baseline, day 42 and day 84).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Peanut Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts |
Dietary Supplement: Peanut
Dietary Supplement: Peanut
|
| Experimental: Control Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack |
Dietary Supplement: Control
Dietary Supplement: High carbohydrate snacks
|
Outcome Measures
Primary Outcome Measures
- Blood glucose [Blood glucose will be measured at day 84.]
glucose, insulin, HbA1c
Secondary Outcome Measures
- Blood lipids level [Blood lipids level will be measured at day 84.]
cholesterol and triglyceride levels
- Blood Inflammatory status [Inflammatory biomarkers will be measured at day 84.]
Inflammatory biomarkers
- Assessment of appetite and other hunger sensations [Appetite and other hunger sensations will be measured at day 84.]
Appetite and other hunger sensations will be assessed using visual analogue scales
- Microbiome [Micriobiome will be measured at day 84.]
fecal microbiome (subset) A subset of study subjects will be measured for fecal microbiome functionality.
- Polyphenol metabolites [Polyphenol metabolites will be measured at day 84.]
Urinary polyphenol metabolites (subset)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
20-65
-
Increased waist circumference : ≥ 90 cm for men and ≥ 80 cm for women
Plus 1 or more of the remaining criteria:
-
Elevated TG level ≥ 1.7 mmo/L
-
Reduced HDL-Cholesterol < 1.03 mmol/L in men and < 1.29 mmol/L in women)
-
Fasting glucose ≥ 5.6 mmol/L
-
Systolic/diastolic blood pressure ≥ 130/85 mmHg.
Exclusion Criteria:
-
Taking lipid lowering medications
-
With known or unknown peanut allergy (or any peanut containing products)
-
Thyroid disease
-
Diabetes mellitus
-
Kidney disease
-
Liver disease
-
Cardiovascular disease or cancer
-
Pregnant or lactating women
-
Heavy alcohol consumption (>14 drinks/week)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Liang Sun | Shanghai | China | 200040 |
Sponsors and Collaborators
- Harvard School of Public Health (HSPH)
Investigators
- Principal Investigator: Xiaoran Liu, PhD, Harvard School of Public Health (HSPH)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB17-0703